University of Copenhagen researchers have developed a prototype patch for treating plaque psoriasis, which may simplify ...

Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of ...

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for its Xarelto blood ...

Researchers at Case Western Reserve University have identified a new target to treat atherosclerosis, a condition where ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

Against the background described above, "betting big" on a topical treatment for plaque psoriasis make a lot of sense, ...

Reviewed by Lexie CornerNov 13 2024 According to a study published in Biomaterials Advances, scientists at the University of ...